Advertisement

Perspectives on Interventional Cancer Pain Management

  • Arvider Gill
  • Oscar A. de Leon-Casasola
Chapter

Abstract

The prevalence of pain among patients with cancer is significant. Despite the development of new medications, the use of multimodal therapy, and the better understanding of the role that interventional technique may play in the management of these patients, uncontrolled pain continues to be significant in first world countries. Studies have shown that pain specialist involvement in the treatment of these patients results in not only improved pain control but also a decrease in side effects. Consequently, oncologists need to be proactive in involving a pain specialist in the management of these patients.

Keywords

Cancer pain Alternative treatment Pain specialist 

References

  1. 1.
    American Cancer Society. Cancer facts & figures 2014. Atlanta: American Cancer Society; 2014.Google Scholar
  2. 2.
    van den Bueuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Parjin J. High prevalence of pain in patients with cancer in a large population-based study in the The Netherlands. Pain. 2007;132:312–20.CrossRefGoogle Scholar
  3. 3.
    Fisch MJ, Lee J-W, Weiss M, Wagner LI, Chang VT, Cella V, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatient with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30:1980–91.CrossRefGoogle Scholar
  4. 4.
    Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Catala E, Bryce DA, Coyne PJ, Pool GE. Randomized clinical trial of an implantable drug delivery sytem compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–9.CrossRefGoogle Scholar
  5. 5.
    de Leon-Casasola OA. Multimodal approaches to the management of neuropathic pain: the role of topical analgesia. J Pain and Symp Manag. 2007;33:356–64.CrossRefGoogle Scholar
  6. 6.
    de Leon-Casasola OA. Current developments in opioid therapy for the management of cancer pain. Clin J Pain. 2008;24(Suppl 10):S3–7.CrossRefGoogle Scholar
  7. 7.
    O’Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med. 2009;122:S22–32.CrossRefGoogle Scholar
  8. 8.
    de Leon-Casasola OA. Multimodal, multiclass, multidisciplinary therapy: the key to better analgesia in the 21st century? Clin J Pain. 2010;26(Suppl 10):S1–2.CrossRefGoogle Scholar
  9. 9.
    Temel JS, Greer JA, Muzikansky A. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–42.CrossRefGoogle Scholar
  10. 10.
    Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy and behavior therapy for chronic pain in adults, excluding headache. Pain. 1999;80:1–13.CrossRefGoogle Scholar
  11. 11.
    Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore. 1994;23:129–38.PubMedGoogle Scholar
  12. 12.
    Gauthier LR, Young A, Dworkin RH, Rodin G, Zimmermann C, Warr D, Librach SL, Moore M, Sheperd FA, Riddell RP, Macpherson A, Melzack R, Gagliese L. Validation of the short-form Mc Gill pain questionnaire-1 in younger and older people with cancer pain. J Pain. 2014;15:756–70.CrossRefGoogle Scholar
  13. 13.
    Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lanteri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29–36.CrossRefGoogle Scholar
  14. 14.
    Bennett M. The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147–57.CrossRefGoogle Scholar
  15. 15.
    Moore TM, Jones T, Browder JH, Daffron S, Passik SD. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009;10:1426–33.CrossRefGoogle Scholar
  16. 16.
    Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6:432–42.CrossRefGoogle Scholar
  17. 17.
    de Leon-Casasola OA. Implementing therapy with opioids in cancer pain. Oncol Nurs Forum. 2008;35(6):S1–6.Google Scholar
  18. 18.
    Wong GY, Schroeder DR, Carns PE, Wilson JI, Martin DP, Kinney MO, Mantilla CB, Warner DO. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer. A randomized controlled trial. JAMA. 2004;291:1092–9.CrossRefGoogle Scholar
  19. 19.
    de Leon-Casasola OA, Kent E, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain. 1993;54:145–51.CrossRefGoogle Scholar
  20. 20.
    Lozano J, de Leon-Casasola OA. Indications for intrathecal therapy in cancer patients. Tech Reg Anesth Pain Manag. 2011;15:147–9.CrossRefGoogle Scholar
  21. 21.
    de Leon-Casasola OA. Implementing and managing intrathecal pumps. Tech Reg Anesth Pain Manag. 2011;15:155–7.CrossRefGoogle Scholar
  22. 22.
    Sparlin J, de Leon-Casasola OA. Intrathecal pump implantation techniques. Tech Reg Anesth Pain Manag. 2011;15:158–61.CrossRefGoogle Scholar
  23. 23.
    de Leon-Casasola OA. Spinal cord and peripheral nerve stimulation techniques for neuropathic pain. J Pain Symp Manag. 2009;38:S28–38.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.The Jacobs School of Medicine and Biomedical Sciences, Department of AnesthesiologyBuffaloUSA
  2. 2.Division of Pain MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations